{
    "clinical_study": {
        "@rank": "3361", 
        "arm_group": {
            "arm_group_label": "Treatment (navitoclax, sorafenib tosylate)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive navitoclax PO QD on days 1-21 (days 1-28 course of 1 only) and sorafenib tosylate PO BID on days 1-21 (days 8-28 of course 1 only). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase I trial studies the side effects and the best dose of navitoclax when given\n      together with sorafenib tosylate in treating patients with solid tumors that have returned\n      (relapsed) or do not respond to treatment (refractory). Navitoclax and sorafenib tosylate\n      may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth."
        }, 
        "brief_title": "Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors", 
        "condition": [
            "Adult Primary Hepatocellular Carcinoma", 
            "Advanced Adult Primary Liver Cancer", 
            "Localized Unresectable Adult Primary Liver Cancer", 
            "Recurrent Adult Primary Liver Cancer", 
            "Unspecified Adult Solid Tumor, Protocol Specific"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Liver Neoplasms", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the maximum tolerated dose (MTD) of the combination of ABT-263 (navitoclax)\n      and sorafenib (sorafenib tosylate) in patients with advanced solid tumors. (Dose escalation\n      cohort) II. To better characterize the toxicity profile of the combination of ABT-263 and\n      sorafenib. (Expansion cohort) III. To identify any activity of this treatment combination in\n      patients with metastatic cancer. (Dose escalation cohort) IV. To seek preliminary evidence\n      of activity of this treatment combination in patients with hepatoma. (Expansion cohort)\n\n      SECONDARY OBJECTIVES:\n\n      I. To determine whether the combination of ABT-263 and sorafenib induces apoptosis that can\n      be detected by peripheral blood biomarker analysis. (Dose escalation cohort) II. To assess\n      peripheral blood biomarkers in a more homogenous population. (Expansion cohort) III. To\n      determine whether treatment is associated with myeloid cell leukemia-1 (Mcl-1) down\n      regulation in hepatocellular carcinoma (HCC) at the maximum tolerated dose (MTD). (Expansion\n      cohort) IV. To assess in a preliminary fashion whether pretreatment tumor cell levels of\n      Mcl-1, B-cell chronic lymphocytic leukemia (CLL)/lymphoma 2 (Bcl-2), BCL2-like 1 (Bcl-xL),\n      BCL2-associated X protein (Bax), and/or BCL2-antagonist/killer 1 (Bak) predict response to\n      this regimen. (Expansion cohort)\n\n      OUTLINE: This is a dose-escalation study of navitoclax.\n\n      Patients receive navitoclax orally (PO) once daily (QD) on days 1-21 (days 1-28 course of 1\n      only) and sorafenib tosylate PO twice daily (BID) on days 1-21 (days 8-28 of course 1 only).\n      Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up at 3 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histologically confirmed malignancy that is metastatic or\n             unresectable and for which standard curative or palliative measures do not exist or\n             are no longer effective\n\n          -  HCC patients only: HCC confirmed by biopsy OR diagnosed by clinical and radiologic\n             criteria; all of the following criteria must be met or a biopsy is required:\n\n               -  Known cirrhosis or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV)\n                  infection\n\n               -  Hypervascular liver masses > 2 cm, and either serum alpha-fetoprotein (AFP) >\n                  400 ng/ml\n\n               -  AFP > three times normal and doubling in value in the antecedent 3 months\n\n               -  In the expansion cohort, prior treatment with sorafenib as first-line therapy\n                  allowed\n\n          -  Any number of the following prior therapies is allowed:\n\n               -  Chemotherapy >= 28 days prior to registration\n\n               -  Mitomycin C/nitrosoureas >= 42 days prior to registration\n\n               -  Immunotherapy >= 28 days prior to registration\n\n               -  Biologic therapy >= 28 days prior to registration\n\n               -  Radiation therapy >= 28 days prior to registration\n\n               -  Radiation to < 25% of bone marrow\n\n          -  HCC patients only: prior regional treatments for liver metastasis are permitted\n             including:\n\n               -  Selective internal radiation therapy such as brachytherapy, CyberKnife,\n                  radiolabelled microsphere embolization, etc.\n\n               -  Hepatic artery chemoembolization\n\n               -  Hepatic artery embolization\n\n               -  Hepatic artery infusional chemotherapy\n\n               -  Radiofrequency ablation\n\n               -  NOTE: patients must be >= 4 weeks from treatment and show progressive disease in\n                  the liver after regional therapy or must have measurable disease outside the\n                  liver\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2\n\n          -  Life expectancy of > 3 months\n\n          -  Leukocytes >= 3,000/mcL\n\n          -  Absolute neutrophil count >= 1,500/mcL (subjects may be treated with hematopoietic\n             growth factors to achieve or maintain this level)\n\n          -  Hemoglobin >= 9.0 g/dL\n\n          -  International normalized ratio (INR) =< 1.4\n\n          -  Platelets >= 100,000/mm^3\n\n          -  Total bilirubin =< 1.5 x upper limit of normal (ULN) (patients with Gilbert's\n             syndrome may have serum bilirubin > 1.5 x ULN)\n\n          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase\n             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])\n             =< 2.5 x institutional ULN\n\n          -  Serum creatinine =< 1.5 times the ULN\n\n          -  Able to swallow and retain oral medication\n\n          -  Negative serum pregnancy test =< 7 days prior to registration for women of\n             childbearing potential\n\n               -  NOTE: women will be considered not of childbearing potential if they are\n                  surgically sterile (bilateral oophorectomy or hysterectomy) and/or\n                  post-menopausal (amenorrheic for at least 12 months)\n\n          -  Ability to understand and the willingness to sign a written informed consent document\n\n        Exclusion Criteria:\n\n          -  Unresolved toxicity of National Cancer Institute Common Terminology Criteria for\n             Adverse Events, version 4.0 (NCI CTCAE v 4.0) grade 2 or higher from previous\n             anti-cancer therapy, except alopecia\n\n          -  Receiving any other investigational agents =< 28 days prior to registration\n\n          -  Known brain metastases (even if treated)\n\n          -  Known portal hypertension or history of variceal bleeding\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to ABT-263 or sorafenib\n\n          -  Current use of anticoagulation; NOTE: use of low-dose anticoagulation medications\n             (such as heparin) that are used to maintain the patency of a central intravenous\n             catheter is allowed\n\n          -  Current use of aspirin =< 7 days prior to registration; NOTE: use is prohibited\n             during the use of ABT-263; subjects who have previously received aspirin therapy for\n             thrombosis prevention may resume a low dose (i.e., maximum 100 mg QD) of aspirin if\n             platelet counts are stable (>= 50,000/mm^3) through 6 weeks of ABT-263\n             administration; all decisions regarding treatment with aspirin therapy will be\n             determined by the principal investigator in conjunction with the medical monitor\n\n          -  Current use of strong cytochrome P450, family 3, subfamily A (CYP3A) inhibitors such\n             as ketoconazole and clarithromycin are not allowed =< 7 days prior to registration;\n             NOTE: use of strong CYP3A is prohibited; use of moderate CYP3A should be used with\n             caution during the use of ABT-263; common cytochrome P450, family 2, subfamily C,\n             polypeptide 8 (CYP2C8) substrates include paclitaxel, statins, and glitazones,\n             whereas cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9) substrates\n             include phenytoin and warfarin; when possible, investigators should switch to\n             alternative medications or monitor the patients closely (particularly in the case of\n             medications that have a narrow therapeutic window such as warfarin)\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements\n\n          -  Any of the following:\n\n               -  Pregnant women\n\n               -  Nursing women\n\n               -  Women of childbearing potential who are unwilling to employ adequate\n                  contraception; NOTE: should a woman become pregnant or suspect she is pregnant\n                  while she or her partner is participating in this study, she should inform her\n                  treating physician immediately; women of child-bearing potential and men must\n                  agree to use adequate contraception using one of the methods listed below prior\n                  to study entry, for the duration of study participation, and up to 90 days\n                  following completion of therapy:\n\n                    -  Total abstinence from sexual intercourse (minimum one complete menstrual\n                       cycle prior to study drug administration)\n\n                    -  Vasectomized male subject or vasectomized partner of female subjects\n\n                    -  Hormonal contraceptives (oral, parenteral, transdermal or vaginal ring) for\n                       at least 3 months prior to study drug administration; if the subject is\n                       currently using a hormonal contraceptive, she should also use a barrier\n                       method during this study and for 1 month after study completion\n\n                    -  Intrauterine device (IUD)\n\n                    -  Double-barrier method: male condom plus diaphragm or vaginal cap with\n                       spermicide (contraceptive sponge, jellies or creams)\n\n                    -  Additionally, male subjects (including those who are vasectomized) whose\n                       partners are pregnant or might be pregnant must agree to use condoms for\n                       the duration of the study and for 90 days following completion of therapy\n\n          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral\n             therapy\n\n          -  Underlying condition predisposing them to bleeding or currently exhibits signs of\n             clinically significant bleeding\n\n          -  Recent history of non-chemotherapy-induced thrombocytopenic-associated bleeding =< 1\n             year prior to the registration\n\n          -  History of cardiovascular disease (e.g., myocardial infraction [MI], thrombotic or\n             thromboembolic event in the last 6 months)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02143401", 
            "org_study_id": "NCI-2014-01043", 
            "secondary_id": [
                "NCI-2014-01043", 
                "MC1315", 
                "9608", 
                "U01CA069912", 
                "P30CA015083"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (navitoclax, sorafenib tosylate)", 
                "description": "Given PO", 
                "intervention_name": "navitoclax", 
                "intervention_type": "Biological", 
                "other_name": [
                    "ABT-263", 
                    "BcI-2 family protein inhibitor ABT-263"
                ]
            }, 
            {
                "arm_group_label": "Treatment (navitoclax, sorafenib tosylate)", 
                "description": "Given PO", 
                "intervention_name": "sorafenib tosylate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BAY 43-9006", 
                    "BAY 43-9006 Tosylate Salt", 
                    "BAY 54-9085", 
                    "Nexavar", 
                    "SFN"
                ]
            }, 
            {
                "arm_group_label": "Treatment (navitoclax, sorafenib tosylate)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Treatment (navitoclax, sorafenib tosylate)", 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sorafenib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "contact": {
                "email": "Costello.brian@mayo.edu", 
                "last_name": "Brian A. Costello", 
                "phone": "507-284-2511"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic"
            }, 
            "investigator": {
                "last_name": "Brian A. Costello", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Trial of ABT-263, a Bcl-2 Inhibitor, and Sorafenib (Nexavar) in Patients With Relapsed or Refractory Solid Organ Tumors", 
        "other_outcome": [
            {
                "description": "To assess changes in each antigen, dot plots will be constructed with H-score on the Y axis and pre-or post-treatment status on the X axis, looking for patterns of change that emerge. To assess whether changes occur predominantly in one direction, a sign test will be applied.", 
                "measure": "Changes in levels of cleaved cytokeratin 18 (expansion cohort only)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to up to completion of study treatment"
            }, 
            {
                "description": "The relationship between pretreatment Mcl-1 expression and clinical response will be examined in a post hoc and exploratory fashion. To assess the relationship between Mcl-1 and response the H score (0-300) vs. response will be graphed. Chi-squared tests will be used to assess significance of relationships between these dichotomous variables and response. In addition, associations between molecular markers and time-to-event variables (progression-free-survival [PFS]) will be illustrated graphically using Kaplan-Meier curves and log-rank tests in an exploratory fashion.", 
                "measure": "Changes in hepatoma Mcl-1 expression level in tumor tissue by immunohistochemistry (expansion cohort only)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to up to day 8"
            }, 
            {
                "description": "Will be summarized descriptively and plotted along time by dose levels and as a whole. The changes of the serum levels of M30/M60 at each time point against pre-treatment baseline will be correlated with toxicity and clinical endpoints. The relationships between M30/M60, caspase 3 and cytochrome c at various time points and dose levels will be explored in longitudinal data analysis. Tissue expression of Mcl-1 will be correlated with serum levels of M30/M60 at different time points and clinical toxicity and tumor response.", 
                "measure": "Change in monoclonal antibody (M)30/M60 levels in serum by enzyme-linked immunosorbent assay (ELISA)", 
                "safety_issue": "No", 
                "time_frame": "Day -7 to up to 72 hours on days 1 and 21"
            }
        ], 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Brian Costello", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "MTD defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients) per NCI CTCAE v. 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "description": "The number and severity of all adverse events (overall, by dose-level, and by tumor group) will be tabulated and summarized in this patient population. The grade 3+ adverse events will also be described and summarized in a similar fashion.", 
                "measure": "Incidence of adverse events as graded per NCI CTCAE v. 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 3 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02143401"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Response will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease. The waterfall plot may be used to display best tumor response. Exploratory analysis of the relationship between response and other clinical endpoints may be performed.", 
                "measure": "Tumor response using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.1", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 months"
            }, 
            {
                "description": "The data on time-related variables will be summarized descriptively.", 
                "measure": "Time until any treatment related toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 3 months"
            }, 
            {
                "description": "The data on time-related variables will be summarized descriptively.", 
                "measure": "Time until treatment related grade 3+ toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 3 months"
            }, 
            {
                "description": "The data on time-related variables will be summarized descriptively.", 
                "measure": "Time until hematologic nadirs (white blood cell, absolute neutrophil count, platelets)", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 months"
            }, 
            {
                "description": "The data on time-related variables will be summarized descriptively.", 
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 months"
            }, 
            {
                "description": "The data on time-related variables will be summarized descriptively.", 
                "measure": "Time to treatment failure", 
                "safety_issue": "No", 
                "time_frame": "From registration to documentation of progression, unacceptable toxicity, or refusal to continue participation by the patient , assessed up to 3 months"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}